FA Connect | Gene Therapy Clinical Trial Update

FA Connect | Gene Therapy Clinical Trial Update

Feb 16th, 2022, 10:00 AM


Rocket Pharma has sponsored gene therapy clinical trials to study the use of autologous (from the patient) stem cells transduced with a lentiviral vector carrying the wild type (normal) FANCA gene. The goal of the study is to determine safety and preliminary efficacy of autologous gene correction for the FANCA gene in hematopoietic stem cells without the use of harmful conditioning agents. Rocket Pharma will present the results to-date from these trials and answer questions.

Event Details: This event will be hosted from 10:00-11:00 a.m. Pacific Time (MST +1, CST +2, EST +3 hours)

Translation: A Spanish interpreter will be available for this virtual event. If you would like to request an interpreter for a different language, please register at least one week prior to the session. We will do our best to fulfill your request. A FARF staff member will email you prior to the event if we are unable to fulfill your request.

Questions? Email Rosie Holcomb (.(JavaScript must be enabled to view this email address))

Speaker Bio:

Jonathan Schwartz is Chief Medical Officer & SVP, Clinical Development for Rocket Pharma. Jonathan was most recently Vice President for Clinical Development at Stemline Therapeutics where he oversaw early development efforts for anticancer immunoconjugate, vaccine and small-molecule platforms. Prior to his role at Stemline, Jonathan had a seven year tenure at ImClone/Eli Lilly, where he oversaw the development of the antiangiogenic monoclonal antibody Ramucirumab (CYRAMZA) from end-of-phase-1 through a phase 3 program resulting in stomach, lung and colorectal cancer approvals by the FDA and international health authorities. Jonathan has also participated in multistage development of several additional monoclonal antibodies.

Prior to joining the industry, Jonathan was Associate Professor of Medicine at the Mount Sinai Medical Center in New York, specializing in the treatment and translational research of hepatobiliary malignancies; he was also Director for the Hematology-Oncology Fellowship training program. Jonathan received a BA in American Civilization from Brown University and an MD from Washington University in St. Louis. He completed post-graduate Internal Medicine and Hematology-Oncology training at the Mount Sinai and New York Presbyterian Hospitals.

Jonathan enjoys running, cooking and gardening and is a foremost authority on 1970s soul and funk music.